JAZZ vs SUPN
JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | JAZZ | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $254.87 | $47.19 | |
| Market cap as of 2026-07-26 | $15.9B | $2.7B | |
| P/E as of 2026-07-26 | 540.72 | n/a | |
| PEG as of 2026-07-26 | 58.02 | n/a | |
| Net margin as of 2026-07-26 | +0.7% | -3.7% | JAZZ higher |
| Gross margin as of 2026-07-26 | +88.0% | +89.7% | SUPN higher |
| Operating margin as of 2026-07-26 | -0.8% | -7.8% | JAZZ higher |
| ROE as of 2026-07-26 | +0.7% | -2.7% | JAZZ higher |
| ROA as of 2026-07-26 | +0.3% | -2.0% | JAZZ higher |
| Debt / equity as of 2026-07-26 | 1.18 | 0.00 | SUPN lower |
| Revenue growth (YoY) as of 2026-07-26 | +9.2% | +16.3% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +5.3% | +2.5% | JAZZ higher |
| Beta as of 2026-07-26 | 0.37 | 0.57 | |
| 1-year return as of 2026-07-23 close | +115.1% | +40.6% | JAZZ higher |
Fundamentals: Finnhub, as of 2026-07-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.